Search
Pork collagen
go.drugbank.com/drugs/DB14100ApprovedThe surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden.
Mixtures: Le-Blen Nano Collagen Peptide SerumDalfampridine
go.drugbank.com/drugs/DB06637ApprovedInvestigationalDalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. … FDA approved on January 22, 2010.
Categories: OCT2 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic IndexLisdexamfetamine
go.drugbank.com/drugs/DB01255ApprovedInvestigationalLisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine,[A40246] covalently attached to the naturally occurring amino acid L-lysine. … [A2230] Lisdexamfetamine is the first chemically formulated prodrug stimulant [A40246] and was first approved by the FDA in April 2008.[A2230] It was also approved by Health Canada in February 2009.
Cetyl alcohol
go.drugbank.com/drugs/DB09494ApprovedCetyl alcohol is present in a waxy white powder or flake form at room temperature, and is insoluble in water and soluble in alcohols and oils [A32209]. … According to the FDA Code of Federal Regulations, cetyl alcohol is a safe synthetic fatty acid in food and in the synthesis of food components under the condition that it contain not less than 98 percent
Avacincaptad pegol
go.drugbank.com/drugs/DB15165ApprovedInvestigational[L47696] AMD is the leading cause of vision loss in developed countries for people over 50 years old, with a global estimate of 170 million individuals affected. … Avacincaptad pegol is an RNA aptamer covalently bound to a branched polyethylene glycol (PEG) molecule.
Selegiline
go.drugbank.com/drugs/DB01037ApprovedInvestigationalVet approvedA selective, irreversible inhibitor of Type B monoamine oxidase. It is used in newly diagnosed patients with Parkinson's disease. … It may slow progression of the clinical disease and delay the requirement for levodopa therapy. It also may be given with levodopa upon onset of disability.
Synonyms: L-DeprenalinCategories: Compounds used in a research, industrial, or household setting, Monoamine Oxidase A Inhibitors for interaction with Monoamine Oxidase A substratesRevumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalMenin is a scaffold protein that interacts with both the wild-type and rearranged KMT2A, which is crucial for KMT2A activity and the maintenance of _HOXA_ expression and leukemogenesis. … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in
Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-Tolazamide
go.drugbank.com/drugs/DB00839ApprovedA sulphonylurea hypoglycemic agent with actions and uses similar to those of chlorpropamide.
Synonyms: N-(p-Toluenesulfonyl)-N'-hexamethyleniminoureaCategories: Drugs Used in DiabetesDienogest
go.drugbank.com/drugs/DB09123ApprovedInvestigationalIt is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. … Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties.
Remibrutinib
go.drugbank.com/drugs/DB16852ApprovedInvestigational[L54101] Bruton's tyrosine kinase plays a role in B cell receptor and Fc receptor signalling, releasing histamine and pro-inflammatory mediators. … Remibrutinib is a selective Bruton's tyrosine kinase inhibitor. The FDA approved remibrutinib on September 30, 2025 as the only oral, targeted treatment for chronic spontaneous urticaria.